https://www.newswire.ca/news-releases/pronai-reports-interim-data-from-wolverine-phase-2-trial-of-pnt2258-in-dlbcl-581947331.html
ProNAi Reports Interim Data from Wolverine Phase 2 Trial of PNT2258 in DLBCL
/CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug development company advancing targeted therapeutics for patients with cancer, today announced...
phase 2 trial
https://www.monjuvihcp.com/
MONJUVI® for DLBCL and FL - Official HCP Site
MONJUVI® (tafasitamab-cxix) is a targeted immunotherapy for use in R/R diffuse large B-cell lymphoma and R/R follicular lymphoma. See Full Prescribing...
dlbclflofficialhcpsite
https://www.dukehealth.org/clinical-trials/directory/pro00119831
EA4231: ViPOR in r/r DLBCL and... | Clinical Trials at Duke
Clinical Trial NCT: NCT06649812 at Duke Health is recruiting patients. View the details of this clinical trial to learn more about participating.
clinical trialsvipordlbclduke
https://www.hmpgloballearningnetwork.com/site/frmc/news/outpatient-epcoritamab-dosing-feasible-rr-dlbcl-study-finds
Outpatient Epcoritamab Dosing Feasible in R/R DLBCL, Study Finds
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory...
outpatientepcoritamabdosingfeasibledlbcl
https://www.esmo.org/oncology-news/vipor-regimen-associated-with-durable-remissions-in-patients-with-specific-molecular-dlbcl-subtypes
ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular DLBCL Subtypes...
associated with
https://www.gilead.com/news/news-details/2016/kite-pharma-completes-enrollment-of-all-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-in-pivotal-multi-center-phase-2-study-of-kte-c19-zuma-1
Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in...
Kite Pharma Completes Enrollment of All Patients with Diffuse Large B Cell Lymphoma DLBCL in Pivotal Multi Center Phase 2 Study of KTE C19 ZUMA 1
diffuse large b cell lymphoma
https://www.technavio.com/talk-to-us?report=IRTNTR73132&type=customization
Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 2.46 Billion from...
diffuse large b cell lymphoma
https://www.hmpgloballearningnetwork.com/site/frmc/news/location-creates-travel-burden-and-treatment-inequities-patients-dlbcl-and-fl
Location Creates Travel Burden and Treatment Inequities for Patients With DLBCL and FL
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for...
https://www.mdedge.com/fedprac/avaho/article/273329/lymphoma-plasma-cell-disorders/early-stage-dlbcl-one-size-no-longer-fits-all
In Early-Stage DLBCL, One Size No Longer Fits All | MDedge
early stageone sizeno longerdlbcl
https://www.hmpgloballearningnetwork.com/site/jcp/conference-coverage/seer-analysis-highlights-risk-factors-advanced-dlbcl-diagnosis
SEER Analysis Highlights Risk Factors for Advanced DLBCL at Diagnosis
A large SEER-based analysis shows that logistic regression can accurately predict advanced-stage diffuse large B-cell lymphoma (DLBCL) at diagnosis,...
risk factorsfor advancedseeranalysishighlights
https://www.fiercebiotech.com/keyword/diffuse-large-b-cell-lymphoma-dlbcl
diffuse large B-cell lymphoma (DLBCL) | Fierce Biotech
diffuse large b cell lymphomadlbclfiercebiotech
https://www.hmpgloballearningnetwork.com/site/onc/videos/novel-updates-dlbcl-and-mcl-treatment-research-2024-asco-meeting
DLBCL and MCL Research from the 2024 ASCO Meeting
John Burke, MD, discusses interesting topics in DLBCL and MCL research presented at the 2024 ASCO Annual Meeting.
from thedlbclmclresearch2024
https://www.technavio.com/talk-to-us?report=IRTNTR73132&type=sample&src=report&block=infographics2
Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 2.46 Billion from...
diffuse large b cell lymphoma
https://www.technavio.com/talk-to-us?type=sample&rfs=epd&src=report&report=IRTNTR73132&cta_name=Download+Now+Button&source_web=report%2Fdiffuse-large-b-cell-lymphoma-dlbcl-therapeutics-market-industry-analysis&main_source=direct
Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 2.46 Billion from...
diffuse large b cell lymphoma
https://www.mdedge.com/fedprac/avaho/article/190006/aggressive-lymphomas/juliet-car-t-cells-go-distance-r/r-dlbcl
JULIET: CAR T cells go the distance in r/r DLBCL | MDedge
car t cellsgo the distancejuliet
https://elifesciences.org/reviewed-preprints/92841/figures
Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity of DLBCL Patients
https://www.technavio.com/talk-to-us?report=IRTNTR73132&type=sample&src=report&block=infographics1
Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 2.46 Billion from...
diffuse large b cell lymphoma